Mikael Sellén

Title: Mikael Sellén: Innovator in Thrombin Inhibition

Introduction

Mikael Sellén is a notable inventor based in Göteborg, Sweden. He has made significant contributions to the field of medicinal chemistry, particularly in the development of prodrugs for thrombin inhibitors. His work is crucial in addressing medical conditions that require effective anticoagulant therapies.

Latest Patents

Mikael Sellén holds a patent for "Prodrugs of thrombin inhibitors." This patent describes compounds that are useful as prodrugs of inhibitors of trypsin-like proteases, such as thrombin. These compounds are particularly relevant in the treatment of conditions where thrombin inhibition is necessary, such as thrombosis.

Career Highlights

Mikael is associated with AstraZeneca AB, a leading global biopharmaceutical company. His role at AstraZeneca has allowed him to work on innovative solutions that address critical health issues. His expertise in the field has positioned him as a valuable asset to the company and the broader scientific community.

Collaborations

Mikael collaborates with esteemed colleagues, including Thomas Antonsson and David Gustafsson. These partnerships enhance the research and development efforts at AstraZeneca, fostering an environment of innovation and discovery.

Conclusion

Mikael Sellén's contributions to thrombin inhibition through his patent and work at AstraZeneca highlight his importance in the field of medicinal chemistry. His innovative approach continues to pave the way for advancements in anticoagulant therapies.